View all news and updates >

Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older

Posted on:

Ipsen

First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity and studied in patients with cerebral palsy

Pivotal study in cerebral palsy patients with lower limb spasticity aged 2 to 17 showed significant improvements in co-primary efficacy endpoints at Week 4 that evaluated Modified Ashworth Scale in ankle plantar flexor muscle tone and Physician’s Global Assessment response to treatment score.

Read the official press release.